BioCentury | Jul 22, 2020
Finance

July 21 Quick Takes: Royalty to reap risdiplam royalties; plus CureVac, Antengene, Citrine, Verona, Novartis, Amicus, Aslan, SAB, Gain

...3H Health Investment and Wu Capital in the financing. A gentlemanly private placement in Verona Verona Pharma plc...
BioCentury | Aug 5, 2019
Clinical News

Aug. 5 Clinical Quick Takes: Emgality meets for migraine with treatment failures; plus Verona, Alkahest-Grifols, Squarex and Denali-Sanofi

..."Amgen Still Head of Class in CGRP-migraine" ). Verona's COPD therapy meets in Phase II Verona Pharma plc...
...Writer AKST6019 (GRF6019, ALK6019) DNL758 Emgality, galcanezumab-gnlm (LY2951742) ensifentrine (RPL554, VMX554, VRP554) SQX770 Alkahest Inc. Denali Therapeutics Inc. Eli Lilly and Co. Grifols S.A. Sanofi Squarex LLC Verona Pharma plc Calcitonin...
BioCentury | Jan 25, 2019
Clinical News

Verona's ensifentrine misses in Phase II for COPD maintenance

...Vernalis plc subsidiary of Ligand Pharmaceuticals Inc. (NASDAQ:LGND). Ligand Pharmaceuticals Inc. (NASDAQ:LGND), San Diego, Calif. Verona Pharma plc...
...dose on day three Status: Phase II data Milestone: NA Jennie Walters RPL554, VMX554, VRP554 Ligand Pharmaceuticals Inc. Vernalis plc Verona Pharma plc Phosphodiesterase-3...
BioCentury | Apr 12, 2018
Company News

Management tracks: Verona, Medigene, NeoPhore

...Respiratory disease company Verona Pharma plc (LSE:VRP; NASDAQ:VRNA) said CMO Kenneth Newman will resign, effective April 30. The...
BioCentury | Mar 30, 2018
Clinical News

Verona's RPL554 meets in Phase IIb for COPD

...Vernalis plc (LSE:VER), which is eligible for milestones and royalties. Vernalis plc (LSE:VER), Winnersh, U.K. Verona Pharma plc...
...Global Assessment of Change (PGIC) Status: Phase IIb data Milestone: Start pivotal trial (2019) Mary Romeo RPL554 VMX554 VRP554 Vernalis plc Verona Pharma plc PDE-4 Phosphodiesterase-3...
BioCentury | Mar 23, 2018
Clinical News

Verona reports Phase IIa data for RPL554 in CF

...Vernalis plc (LSE:VER), which is eligible for milestones and royalties. Vernalis plc (LSE:VER), Winnersh, U.K. Verona Pharma plc...
...24 hours, forced vital capacity (FVC) and safety Status: Phase IIa data Milestone: NA Mary Romeo RPL554 VMX554 VRP554 Vernalis plc Verona Pharma plc PDE-4 Phosphodiesterase-3...
BioCentury | Nov 10, 2017
Financial News

Aisling closes fund IV at $280M

...but also targets ex-U.S. companies that go public on a U.S. exchange. Elms pointed to Verona Pharma plc...
BioCentury | Nov 2, 2017
Financial News

Aisling closes fund IV at $280 million

...but also targets ex-U.S. companies that go public on a U.S. exchange. Elms pointed to Verona Pharma plc...
BioCentury | Oct 13, 2017
Clinical News

Verona reports Phase IIa data for RPL554 in COPD

...Vernalis plc (LSE:VER), which is eligible for milestones and royalties. Vernalis plc (LSE:VER), Winnersh, U.K. Verona Pharma plc...
...action, functional residual capacity and residual lung volume Status: Phase IIa data Milestone: NA Alicia Parker RPL554 VMX554 VRP554 Vernalis plc Verona Pharma plc Phosphodiesterase-3...
BioCentury | Jul 7, 2017
Finance

Generalists needed

...Inc. (NASDAQ:RXDX) 5/4/17 $88.4 $345.7 $581.8 68% CytRx Corp. (NASDAQ:CYTR) 4/28/17 $15.0 $73.7 $95.8 30% Verona Pharma plc...
Items per page:
1 - 10 of 63
BioCentury | Jul 22, 2020
Finance

July 21 Quick Takes: Royalty to reap risdiplam royalties; plus CureVac, Antengene, Citrine, Verona, Novartis, Amicus, Aslan, SAB, Gain

...3H Health Investment and Wu Capital in the financing. A gentlemanly private placement in Verona Verona Pharma plc...
BioCentury | Aug 5, 2019
Clinical News

Aug. 5 Clinical Quick Takes: Emgality meets for migraine with treatment failures; plus Verona, Alkahest-Grifols, Squarex and Denali-Sanofi

..."Amgen Still Head of Class in CGRP-migraine" ). Verona's COPD therapy meets in Phase II Verona Pharma plc...
...Writer AKST6019 (GRF6019, ALK6019) DNL758 Emgality, galcanezumab-gnlm (LY2951742) ensifentrine (RPL554, VMX554, VRP554) SQX770 Alkahest Inc. Denali Therapeutics Inc. Eli Lilly and Co. Grifols S.A. Sanofi Squarex LLC Verona Pharma plc Calcitonin...
BioCentury | Jan 25, 2019
Clinical News

Verona's ensifentrine misses in Phase II for COPD maintenance

...Vernalis plc subsidiary of Ligand Pharmaceuticals Inc. (NASDAQ:LGND). Ligand Pharmaceuticals Inc. (NASDAQ:LGND), San Diego, Calif. Verona Pharma plc...
...dose on day three Status: Phase II data Milestone: NA Jennie Walters RPL554, VMX554, VRP554 Ligand Pharmaceuticals Inc. Vernalis plc Verona Pharma plc Phosphodiesterase-3...
BioCentury | Apr 12, 2018
Company News

Management tracks: Verona, Medigene, NeoPhore

...Respiratory disease company Verona Pharma plc (LSE:VRP; NASDAQ:VRNA) said CMO Kenneth Newman will resign, effective April 30. The...
BioCentury | Mar 30, 2018
Clinical News

Verona's RPL554 meets in Phase IIb for COPD

...Vernalis plc (LSE:VER), which is eligible for milestones and royalties. Vernalis plc (LSE:VER), Winnersh, U.K. Verona Pharma plc...
...Global Assessment of Change (PGIC) Status: Phase IIb data Milestone: Start pivotal trial (2019) Mary Romeo RPL554 VMX554 VRP554 Vernalis plc Verona Pharma plc PDE-4 Phosphodiesterase-3...
BioCentury | Mar 23, 2018
Clinical News

Verona reports Phase IIa data for RPL554 in CF

...Vernalis plc (LSE:VER), which is eligible for milestones and royalties. Vernalis plc (LSE:VER), Winnersh, U.K. Verona Pharma plc...
...24 hours, forced vital capacity (FVC) and safety Status: Phase IIa data Milestone: NA Mary Romeo RPL554 VMX554 VRP554 Vernalis plc Verona Pharma plc PDE-4 Phosphodiesterase-3...
BioCentury | Nov 10, 2017
Financial News

Aisling closes fund IV at $280M

...but also targets ex-U.S. companies that go public on a U.S. exchange. Elms pointed to Verona Pharma plc...
BioCentury | Nov 2, 2017
Financial News

Aisling closes fund IV at $280 million

...but also targets ex-U.S. companies that go public on a U.S. exchange. Elms pointed to Verona Pharma plc...
BioCentury | Oct 13, 2017
Clinical News

Verona reports Phase IIa data for RPL554 in COPD

...Vernalis plc (LSE:VER), which is eligible for milestones and royalties. Vernalis plc (LSE:VER), Winnersh, U.K. Verona Pharma plc...
...action, functional residual capacity and residual lung volume Status: Phase IIa data Milestone: NA Alicia Parker RPL554 VMX554 VRP554 Vernalis plc Verona Pharma plc Phosphodiesterase-3...
BioCentury | Jul 7, 2017
Finance

Generalists needed

...Inc. (NASDAQ:RXDX) 5/4/17 $88.4 $345.7 $581.8 68% CytRx Corp. (NASDAQ:CYTR) 4/28/17 $15.0 $73.7 $95.8 30% Verona Pharma plc...
Items per page:
1 - 10 of 63